Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-10T05:09:47.909Z Has data issue: false hasContentIssue false

Clinical and demographic features associated with infections with extended-spectrum beta-lactamase–producing Escherichia coli in a health system in Maine, 2017

Published online by Cambridge University Press:  28 June 2021

Eugene W. Liu*
Affiliation:
Infectious Disease, Eastern Maine Medical Center, Northern Light Health, Bangor, Maine
Sarah N. Buss
Affiliation:
Clinical Microbiology, Northern Light Laboratory, Northern Light Health, Bangor, Maine
Jennifer L. Trumbo
Affiliation:
Clinical Research Center, Northern Light Health, Bangor, Maine
Tina M. Temples
Affiliation:
Clinical Research Center, Northern Light Health, Bangor, Maine
*
Author for correspondence: E. W. Liu, Suite 412, 417 State Street, Bangor, ME 04401. E-mail: eliu@northernlight.org

Abstract

In this case–case control study, we identified receipt of β-lactam antibiotics and older age as independently associated with increased infection risk with ESBL-producing Escherichia coli among residents aged 20–88 years in a rural Maine hospital system where the infection prevalence of antibiotic-resistant E. coli is low.

Type
Concise Communication
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Emergence of multidrug-resistant bacteria is thought to be associated with misuse of antibiotics. One major set of resistance genes are extended-spectrum β-lactamases (ESBLs), which produce enzymes hydrolyzing the β-lactam ring, and are commonly found in Escherichia coli. Prior studies have identified various risk factors for ESBL-producing bacterial infections: a history of carbapenem-resistant colonization/infection, recent international hospitalization, Reference Goodman, Lessler and Cosgrove1 presence of a urinary catheter, diabetes, hospitalization in the past year, Reference Park, Adams-Haduch and Shutt2 exposure to health care, previous antimicrobial use, Reference Kang, Wi and Lee3 surgery, and proton pump inhibitor (PPI) use. Reference Sogaard, Heide-Jorgensen, Vandenbroucke, Schonheyder and Vandenbroucke-Grauls4 In Maine, the prevalence of drug-resistant E. coli is low (2.7% vs 7.5% nationwide). 5 In this study, we investigated risk factors for ESBL-producing E. coli infections at Eastern Maine Medical Center (EMMC), a tertiary hospital, and in 4 affiliated community hospitals and outpatient clinics serving >40% of the Maine population in its rural central and northeastern regions. In this rural setting, we hypothesized that the risk of drug-resistant infection is low due to low levels of exposure to healthcare settings or antibiotics. Understanding factors contributing to a lower prevalence of ESBL-producing E. coli in Maine may inform efforts to prevent emergence of antibiotic-resistant bacteria.

Methods

Study participants were identified from laboratory reports: residents of Maine aged 20–88 years with culture specimens in which E. coli was isolated during 2017. Individuals aged >88 years were excluded to prevent personal identification. Case patients were defined as patients with at least 1 E. coli isolate resistant to ceftriaxone (thus presumed to produce an ESBL). Control patients were those with E. coli isolates that were all susceptible to ceftriaxone.

Data elements of sex at birth, race, age, and ZIP code to determine residence in a Health Resources and Services Administration defined medically underserved area (MUA) 6 were extracted from the Northern Light electronic medical record. For each study participant, an isolate of interest was determined, defined as the first ceftriaxone-resistant E. coli isolate in cases and the first ceftriaxone-susceptible isolate in controls. For each isolate of interest and corresponding specimen collection date, we extracted data on antibiotics and PPIs received in the prior 6 months (180 days), specimen type, number of primary care visits and hospitalizations of each subject in the prior 12 months, and associated diagnosis codes.

Analyses were performed using R statistical software (R Foundation for Statistical Computing, Vienna, Austria). We calculated Charlson comorbidity scores from diagnosis codes using the comorbidity package. Reference Gasparini7,Reference Charlson, Pompei, Ales and MacKenzie8 We performed logistic regression using the survival package, Reference Therneau and Grambsch9,Reference Therneau10 first by single factors. Factors with significant odds ratios on simple logistic regression were used in multiple logistic regression with bidirectional stepwise variable selection by the Akaike Information Criterion to identify independent risk factors.

This study was approved by the EMMC Institutional Review Board with an exempt determination for which consent is not required, wherein the use of protected health information involves no more than a minimal risk to the privacy of individuals and could not practically be conducted without a waiver and use of protected health information.

Results

Demographic features associated with infection

We identified 60 case patients (6%) and 1,017 controls (94%) (Table 1). Male sex (OR, 1.96; 95% confidence interval [CI], 1.42–4.04) and older age (OR, 1.03; 95% CI, 1.02–1.05) were associated with infection with an ESBL-producing E. coli on simple logistic regression. Race was not associated with infection, with 97% of both case patients and controls identifying as white. Residence in a MUA (OR, 0.56; 95% CI, 0.33–0.95) was negatively associated with infection.

Table 1. Associations Between Demographic and Clinical Features of Patients and Infection With an Extended-Spectrum β-Lactamase–Producing E. coli Estimated With Simple Logistic Regression Models in a Case–Control Study—Maine, 2017

***P < .001; **P < .01; *P < .05.

aCovariate included in the final multiple logistic regression model by bidirectional stepwise variable selection.

bCovariate with significant association with infection with an ESBL-producing E. coli isolate in the final multiple logistic regression model.

Clinical predictors of infection

Most E. coli isolates of interest in both cases and controls were from urine (97% of cases, 96% of controls) (Table 1). No isolates from other sources were associated with infection compared to isolates from the urine. The number of hospitalizations was associated with infection (OR, 1.29; 95% CI, 1.08–1.54), but not the number of primary care visits. Weighted Charlson comorbidity score (OR, 1.25; 95% CI, 1.15–1.37) and receipt of PPIs (OR, 3.00; 95% CI, 1.64–5.49) were also associated with infection.

Antibiotic usage associated with infection

Receipt of any β-lactam in the 6 months prior to collection of an E. coli isolate of interest was associated with infection (OR, 5.70; 95% CI, 3.33–9.76) (Supplementary Table 2 online). Within this class of antibiotics, multiple β-lactam antibiotics were associated with infection: piperacillin/tazobactam, cefazolin, ceftriaxone, and cefpodoxime. Receipt of azithromycin (OR, 4.77; 95% CI, 1.53–14.85) was also associated with infection.

Table 2. Risk Factors for Infection With an ESBL Isolate, as Estimated With a Multiple Logistic Regression Model in a Case–Control Study—Maine, 2017 with 60 Cases and 1,017 Controls

***P < .001, **P < .01.

Independent risk factors for infection

To identify independent risk factors, we performed multiple logistic regression with bidirectional stepwise variable selection on covariates associated with infection on simple logistic regression: sex, age, MUA residence, number of hospitalizations, weighted Charlson comorbidity score, receipt of PPIs, β-lactam antibiotics, and azithromycin. Bidirectional stepwise regression indicated that age, MUA residence, and receipt of β-lactam antibiotics should be included in our multiple logistic model. In this model, age (OR, 1.02; 95% CI, 1.01–1.04) and receipt of a β-lactam antibiotics (OR, 4.63; 95% CI, 2.57–8.32) were associated with infection, whereas MUA residence (OR, 0.60; 95% CI, 0.34–1.04) was not (Table 2).

Discussion

In this study, we identified receipt of β-lactam antibiotics and age as independent risk factors for infection with an ESBL-producing E. coli isolate in a hospital system in rural Maine in 2017. This association of receipt of β-lactams and infection is consistent with the selective pressure that β-lactams apply on E. coli variants, allowing ESBL-producing E. coli to predominate and cause infection. The association with age may be a marker for past exposure to β-lactam antibiotics or nosocomial infection with ESBL-producing E. coli as we only examined antibiotic exposures 6 months prior to the collection date of the isolate of interest. Recent receipt of β-lactam antibiotics (within 6 months) may have selected out archived ESBL-producing E. coli variants, the numbers of which may be correlated with age.

Receipt of azithromycin, a non–β-lactam, was associated with infection on simple logistic regression, but not independently, and may be due to the practice of using azithromycin for empiric antibiotic coverage with β-lactam antibiotics. Similarly, the association seen with receipt of PPIs only on simple logistic regression may be due to their use as prophylaxis against stress ulcers during hospitalizations.

With respect to the degree of exposure to healthcare, although we noted an association between infection and the number of hospitalizations and Charlson comorbidity scores, and a negative association with MUA residence on simple logistic regression, none of these factors were independently associated with infection. This finding suggests confounding with receipt of β-lactam antibiotics.

This study has several limitations. We examined receipt of antibiotics over 6 months; thus, the effect of remote receipt of antibiotics is unknown. The degree to which age interacts with receipt of β-lactams also remains unclear. Furthermore, we did not account for asymptomatic carriers of ESBL-producing E. coli nor for treatments outside the Northern Light Health System. The mechanisms of resistance to ceftriaxone of E. coli isolates are unknown in this study; presumed ESBL production could arise from plasmid or chromosome mediated genes. Finally, we were unable to provide direct evidence to explain the overall decreased prevalence of drug-resistant E. coli in Maine.

Despite the limitations of this study, we identified receipt of β-lactams and age as independent risk factors associated with infection with ESBL-producing E. coli. The association of β-lactam use and ESBL-producing E. coli highlights the importance of antimicrobial stewardship to prevent further emergence of antibiotic-resistant bacteria.

Supplementary material

To view supplementary material for this article, please visit https://doi.org/10.1017/ash.2021.169

Acknowledgments

Valerie Torske from Northern Light Health Information Services Integration & Data Management assisted with data extraction from the Northern Light EMR. Prashant Mittal, Clinial Assistant Professor at the University of New Hampshire, provided statistical consultation. The findings and conclusions in this report are those of the authors and do not necessarily represent the view of Northern Light Eastern Maine Medical Center nor the Northern Light Health System.

Financial support

This work was supported by the Northern Light Eastern Maine Medical Center, Bangor, Maine.

Conflicts of interest

All authors report no conflicts of interest relevant to this article.

References

Goodman, KE, Lessler, J, Cosgrove, SE, et al. A clinical decision tree to predict whether a bacteremic patient is infected with an extended-spectrum β-lactamase–producing organism. Clin Infect Dis 2016;63:896903.CrossRefGoogle ScholarPubMed
Park, YS, Adams-Haduch, JM, Shutt, KA, et al Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States. Antimicrob Agents Chemother 2012;56:18701876.CrossRefGoogle ScholarPubMed
Kang, CI, Wi, YM, Lee, MY, et al. Epidemiology and risk factors of community onset infections caused by extended-spectrum beta-lactamase–producing Escherichia coli strains. J Clin Microbiol 2012;50:312317.CrossRefGoogle ScholarPubMed
Sogaard, M, Heide-Jorgensen, U, Vandenbroucke, JP, Schonheyder, HC, Vandenbroucke-Grauls, CMJE. Risk factors for extended-spectrum beta-lactamase–producing Escherichia coli urinary tract infection in the community in Denmark: a case–control study. Clin Microbiol Infect 2017;23:952960.CrossRefGoogle ScholarPubMed
CDC Antibiotic Resistance Patient Safety Atlas, 2017. Centers for Disease Control and Prevention website. https://gis.cdc.gov/grasp/PSA/MapView.html. Published 2017. Accessed May 8, 2019.Google Scholar
Shortage areas. Health Resources and Services Administration website. https://data.hrsa.gov/topics/health-workforce/shortage-areas. Accessed February 28, 2021.Google Scholar
Gasparini, A. Comorbidity: an R package for computing comorbidity scores. 2018;3:648.Google Scholar
Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373383.CrossRefGoogle ScholarPubMed
Therneau, TM, Grambsch, PM. Modeling Survival Data: Extending the Cox Model. New York: Springer, 2000.CrossRefGoogle Scholar
Therneau, T. A Package for survival analysis in R. CRAN.R Project website. https://CRAN.R-project.org/package=survival. Published 2020. Accessed June 7, 2020.Google Scholar
Figure 0

Table 1. Associations Between Demographic and Clinical Features of Patients and Infection With an Extended-Spectrum β-Lactamase–Producing E. coli Estimated With Simple Logistic Regression Models in a Case–Control Study—Maine, 2017

Figure 1

Table 2. Risk Factors for Infection With an ESBL Isolate, as Estimated With a Multiple Logistic Regression Model in a Case–Control Study—Maine, 2017 with 60 Cases and 1,017 Controls

Supplementary material: File

Liu et al. supplementary material

Liu et al. supplementary material

Download Liu et al. supplementary material(File)
File 20.7 KB